Peptide·modified or textual
ATLPC0001106
ATLPC0001106
HADGSFSDEMNTILDNLAAR DFINWLIQTKITD
Routes
- Length1 aa
ATLPC0001106
HADGSFSDEMNTILDNLAAR DFINWLIQTKITD
Reviewed sequence, HELM, or SMILES representation used to interpret this peptide identity.
Molecular graph, chemical representation, 3D references, and covalent topology when available.
Computed sequence-derived descriptors and any measured physicochemical evidence such as lipophilicity.
Product-level route, label, and clinical context that frames peptide-level evidence.
How stable is the peptide in biological matrices or protease systems?
What evidence describes clearance or persistence?
Cross-domain evidence distribution, traceability, and measurement-level detail for this peptide.
Reference-level support for checking reported names, sequence notation, and peptide identity agreement.
Stable record access, analysis-ready files, and scripted retrieval for reproducing this profile view.
Are molecular graph, topology, or 3D coordinates available?
Can basic developability descriptors be computed?
Is this peptide linked to approved or named product context?
What evidence describes systemic exposure or absorption?
What is known about distribution, binding, permeability, or barrier crossing?
What safety, toxicity, or tolerability evidence is attached?
Reported sequence notation was converted to parent-residue display for visualization; the original notation remains shown below.
Normalized for positional visualization, not a replacement for the reported modified notation.
X
Original notation retained for interpretation and comparison.
HADGSFSDEMNTILDNLAAR DFINWLIQTKITD
Interpretation: Evidence should be compared across compatible peptide identities and peptidoforms. A sequence-only match may not be equivalent when terminal modifications, stereochemistry, cyclization, or cross-links differ.
XPolymer notation for modified peptide representation when available.
Not availableChemical graph string used for atom-level 2D depiction when available.
Not availableA reviewed SMILES is required before a 2D molecular depiction can be shown. Sequence and HELM remain useful for identity interpretation, but they do not replace a chemical graph.
| Link | Method | Confidence | Match |
|---|---|---|---|
| Open |
No disulfide, staple, coordination, other cross-link, or residue-level modification annotation is attached to this peptide in the current release.
Interpretation: A 2D graph describes connectivity, not conformation. A 3D reference describes one coordinate model or solved state, not the full ensemble. ADMET interpretation should account for peptidoform, topology, and assay context together.
A280 (1 g/L) ≈ 1.46
Structure-derived descriptors are not shown because this identity has no resolved chemical structure (SMILES). This is a known coverage gap for disulfide-rich and unresolved peptidoforms, not a computation error.
Reviewed observations retained without being collapsed into comparable values.
Endpoints define the scientific questions in this domain; the measurements below carry the values and assay context.
Serum/plasma stability and protease stability evidence.
The same three research-facing layers are used across ADMETatlas.
Rows are grouped by endpoint so value, assay context, interpretation layer, and reference can be checked in place.
| # | Value | Evidence layer | Assay / model | Condition | Reference |
|---|---|---|---|---|---|
| 1 | 6.8 ±0.8 minutes 408 seconds | Comparable | ELISA · porcine · Infused into blood of pigs | Pig plasma proteases · in vivo | Open |
| 2 | 9.9 ±0.8 minutes 594 seconds | Comparable | ELISA · porcine · Infused into blood of pigs | Pig plasma proteases with valine-pyrrolidide (DPP-IV inhibitor) · in vivo | Open |
| 3 | approx 120 Minutes approx 7200 seconds | Comparable | GLP-2 (1–33) specific radioimmunoassay · human · Adult human plasma | Route: SC · Dose/window: 8 μg/kg · Human plasma protease · In Vivo | Open |
| 4 | approx 45 Minutes approx 2700 seconds | Comparable | GLP-2 (1–33) specific radioimmunoassay · human · Infant human plasma | Route: SC · Dose/window: 2.5 μg/kg · Time: Samples were taken prior to GLP-2 administration and at 60, 90 and 180 min post injection on Day 3 of therapy... · Human plasma protease · In Vivo | Open |
| 5 | 10.4 Hours 37440 seconds | Comparable | LC-MS · human · Human plasma | Route: IV · Dose/window: 1 mg · Time: Blood sampling for a pharmacokineticanalysis in these subjects was conducted pre-dose and at 5,10, 15, 20, 25... · Human plasma protease · In Vivo | Open |
| 6 | 254 Hours 914400 seconds | Comparable | LC-MS · human · Human plasma after SC glepaglutide 5 mg after 6 once-weekly doses | Route: SC glepaglutide 10 mg after 6 once-weekly doses · Dose/window: 10 mg · Time: blood sampling in subjects receiving 5 and 10 mg of glepaglutide once weekly occurred at the day 1 visit (pre... · Human plasma protease · In Vivo | Open |
| 7 | 88.3 Hours 317880 seconds | Comparable | LC-MS · human · Human plasma after SC glepaglutide 5 mg after 6 once-weekly doses | Route: SC glepaglutide 10 mg after 6 once-weekly doses · Dose/window: 10 mg · Time: blood sampling in subjects receiving 5 and 10 mg of glepaglutide once weekly occurred at the day 1 visit (pre... · Human plasma protease · In Vivo | Open |
| 8 | 228 Hours 820800 seconds | Comparable | LC-MS · human · Human plasma after SC glepaglutide 5 mg after 6 once-weekly doses | Route: SC glepaglutide 5 mg after 6 once-weekly doses · Dose/window: 5 mg · Time: blood sampling in subjects receiving 5 and 10 mg of glepaglutide once weekly occurred at the day 1 visit (pre... · Human plasma protease · In Vivo | Open |
| 9 | 384 seconds | Comparable | LC-MS/MS · rat · Rats plasma | Dose/window: 1 mg/kg · Time: Blood samples were collected at multiple time points up to 6 h post injection · Rats plasma protease · In Vivo | Open |
| 10 | 16524 seconds | Comparable | natural · rat · Rats plasma | Dose/window: 2 mg/mL · Time: Blood samples were collected from the tail vein at 0, 1, 2, 3, 4, 5,6, 9 and 12 h after administration · Rats plasma protease · In Vivo | Open |
Interpretation: In vitro stability, protease stability, and percent-remaining measurements are not collapsed into one value.
Reviewed observations retained without being collapsed into comparable values.
Endpoints define the scientific questions in this domain; the measurements below carry the values and assay context.
Clearance and half-life evidence.
The same three research-facing layers are used across ADMETatlas.
Rows are grouped by endpoint so value, assay context, interpretation layer, and reference can be checked in place.
| # | Value | Evidence layer | Assay / model | Condition | Reference |
|---|---|---|---|---|---|
| 1 | Observation Increased | Reported | natural | in vivo | Open |
Interpretation: Clearance and half-life require route, matrix, species/population, and time-scale context before comparison.
Reported sequence string matches the current peptide notation.
Reported notation differs, but resolves to the same parent-residue display.
Reported notation does not resolve to the current display sequence.
Grouped by reference link, with endpoint scope and reported identity kept visible.
| Reference | Supports | Reported identity | Records |
|---|---|---|---|
PubMed 36323988 | Stability Serum Plasma Stability | No reported alias HADGSFSDEMNTILDNLAAR DFINWLIQTKITDexact | 4 identity 4 evidence |
PubMed 17107718 | Stability Serum Plasma Stability | No reported alias HADGSFSDEMNTILDNLAAR DFINWLIQTKITDexact | 2 identity 2 evidence |
PubMed 28209419 | Stability Serum Plasma Stability | No reported alias HADGSFSDEMNTILDNLAAR DFINWLIQTKITDexact | 2 identity 2 evidence |
PubMed 28522195 | Stability Serum Plasma Stability | No reported alias HADGSFSDEMNTILDNLAAR DFINWLIQTKITDexact | 1 identity 1 evidence |
PubMed 32075870 | Stability Serum Plasma Stability | No reported alias HADGSFSDEMNTILDNLAAR DFINWLIQTKITDexact | 1 identity 1 evidence |
Reference link | Persistence Half Life | No reported alias HADGSFSDEMNTILDNLAAR DFINWLIQTKITDexact | 1 identity 1 evidence |
Interpretation: Reference links and reported notations help confirm that measurements point to the same peptide identity or a compatible peptidoform. ADMET interpretation still belongs to the endpoint modules above, where assay/model and condition context are shown with each measurement.
Identity, sequence, profile-level fields, and current release view metadata.
The request returns the same structured peptide record used by this profile. Measurement downloads use the same peptide identifier and public release visibility.
curl -sS 'https://admetatlas.scbdd.com/api/v1/peptides/ATLPC0001106' \
-H 'accept: application/json' \
-H 'X-Visibility: public_release'Interpretation: Use these files as the reproducible data package for this peptide profile. Cross-peptide comparison still depends on compatible endpoints, assays, species or model systems, route, dose, matrix, and evidence layer.
Features are shown only when a reported notation or topology record supports them.
Reported token HADGSFSDEMNTILDNLAAR DFINWLIQTKITD is not one of the 20 standard residue symbols in this display.
| Experimental structure match |
| experimental |
| 33 aa |
The identity reference does not expose a sequence string.
HADGSFSDEMNTILDNLAAR DFINWLIQTKITD
HADGSFSDEMNTILDNLAAR DFINWLIQTKITD
Endpoint-level measurements attached to this peptide, suitable for review or reanalysis.
Nested peptide record for scripted retrieval, including identity and evidence context.